Almirall presents five-year EADV data: Almirall stock gains 1.48 percent

Published on 10/06/2026 at 09:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half sales rose 7.50 percent to EUR 602.70 million in 2026. Almirall stock costs EUR 10.28 on October 6, 2026 after EUR 10.13.

Extreme Nahaufnahme einer verwirbelten Hautcreme mit glänzenden Tröpfchen — Almirall S.A. (ES0157097017) zeigt eine Makroaufnahme einer Dermatologie-Cremetextur mit glänzenden Gel-Tröpfchen detailliert, Illustration mit AI erstellt.

Almirall (ISIN ES0157097017) was trading at EUR 10.28 at Lang & Schwarz on October 6, 2026 at 9:30 a.m. CEST, up 1.48 percent versus the prior close of EUR 10.13. On September 30, 2026, Almirall presented five-year data from the ADlong extension study for lebrikizumab at the European Academy of Dermatology and Venereology Congress. The company said the results showed sustained skin and itch responses in patients with atopic dermatitis.

Five-year data strengthens the pipeline

The EADV program included more than 20 abstracts covering atopic dermatitis, psoriasis and actinic keratosis, giving the company a broad medical backdrop for its dermatology portfolio. The ADlong data extend the evidence base for lebrikizumab beyond the initial launch phase and support Almirall's strategy of building value through long-term treatment outcomes.

That scientific update follows a stronger financial first half. According to Business Wire on September 30, 2026, first-half 2026 net sales rose 7.50 percent year over year to EUR 602.70 million, while EBITDA increased 23.70 percent to EUR 150.70 million.

Margins reach the 2028 ambition early

Almirall's first-half EBITDA margin reached 25.00 percent, compared with 21.70 percent in the first half of 2025. The 3.30 percentage-point improvement matters because it brings a stated 2028 margin ambition into the current operating picture, although management also expects higher research and development and promotional spending later in 2026.

The company reiterated full-year 2026 guidance for net sales growth of 9.00 percent to 12.00 percent and EBITDA of EUR 270.00 million to EUR 290.00 million. The next scheduled reporting date is November 9, 2026, when Almirall plans to publish its first nine-month 2026 financial results, according to its investor calendar.

Analyst target remains above the price

Jefferies reiterated a Buy rating and a EUR 16.00 price target for Almirall on September 11, 2026, according to Bolsamania. That target is materially above the Lang & Schwarz price, but the valuation case remains tied to execution in Ebglyss, Ilumetri and the wider medical dermatology pipeline.

Stock trades above prior close

Almirall stock was trading at EUR 10.28 at Lang & Schwarz on October 6, 2026 at 9:30 a.m. CEST, up 1.48 percent versus the Lang & Schwarz prior close of EUR 10.13 on October 5, 2026. The stock's 52-week range was EUR 9.75 to EUR 13.98, while market capitalization stood at EUR 2.2 billion as of October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Almirall stock.